Up-to-date on the evidence linking miRNA-related epitranscriptomic modifications and disease settings. Can these modifications affect cross-kingdom regulation?

dc.contributor.authorTome-Carneiro, Joao
dc.contributor.authorLopez de las Hazas, Maria-Carmen
dc.contributor.authorBoughanem, Hatim
dc.contributor.authorBottcher, Yvonne
dc.contributor.authorCayir, Akin
dc.contributor.authorMacias Gonzalez, Manuel
dc.contributor.authorDavalos, Alberto
dc.contributor.authoraffiliation[Tome-Carneiro, Joao] CEI UAM CSIM, Lab Funct Foods, Madrid Inst Adv Studies IMDEA Food, Madrid, Spain
dc.contributor.authoraffiliation[Lopez de las Hazas, Maria-Carmen] CEI UAM CSIC, Lab Epigenet Lipid Metab, Madrid Inst Adv Studies IMDEA Food, Madrid, Spain
dc.contributor.authoraffiliation[Davalos, Alberto] CEI UAM CSIC, Lab Epigenet Lipid Metab, Madrid Inst Adv Studies IMDEA Food, Madrid, Spain
dc.contributor.authoraffiliation[Boughanem, Hatim] Hosp Virgen de La Victoria, Inst Invest Biomed Malaga Ibima, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain
dc.contributor.authoraffiliation[Macias Gonzalez, Manuel] Hosp Virgen de La Victoria, Inst Invest Biomed Malaga Ibima, Unidad Gest Clin Endocrinol & Nutr, Malaga, Spain
dc.contributor.authoraffiliation[Boughanem, Hatim] Inst Salud Carlos III Isciii, Mp Fisiopatol Obesidad & Nutr Ciberobn, Consorcio Ciber, Madrid, Spain
dc.contributor.authoraffiliation[Macias Gonzalez, Manuel] Inst Salud Carlos III Isciii, Mp Fisiopatol Obesidad & Nutr Ciberobn, Consorcio Ciber, Madrid, Spain
dc.contributor.authoraffiliation[Bottcher, Yvonne] Univ Oslo, Inst Clin Med, Dept Clin Mol Biol EpiGen, Oslo, Norway
dc.contributor.authoraffiliation[Cayir, Akin] Univ Oslo, Inst Clin Med, Dept Clin Mol Biol EpiGen, Oslo, Norway
dc.contributor.authoraffiliation[Bottcher, Yvonne] Akershus Univ Sykehus, Dept Med Serv & Tech EpiGen, Lorenskog, Norway
dc.contributor.authoraffiliation[Boughanem, Hatim] Canakkale Onsekiz Mart Univ, Vocat Hlth Coll, Canakkale, Turkey
dc.contributor.authoraffiliation[Cayir, Akin] Canakkale Onsekiz Mart Univ, Vocat Hlth Coll, Canakkale, Turkey
dc.contributor.funderCOST (European Cooperation in Science and Technology COST EPITRAN)
dc.contributor.funderSpanish 'Agencia Estatal de Investigacion'
dc.contributor.funderEuropean FEDER Funds (agencia estatal de investigacion and European feder funds)
dc.contributor.funder'Centros de Investigacion En Red' (CIBER) of the 'Instituto de Salud Carlos III' (ISCIII)
dc.contributor.funderEuropean Regional Development Fund (FEDER)
dc.contributor.funderNicolas Monardes Programme from the 'Servicio Andaluz de Salud, Junta de Andalucia', Spain
dc.contributor.funderCentro de Investigacion Biomedica en Red-Fisiopatologia de la Obesidad y Nutricion
dc.date.accessioned2025-01-07T15:12:29Z
dc.date.available2025-01-07T15:12:29Z
dc.date.issued2021-12-01
dc.description.abstractThe field of epitranscriptomics is rapidly developing. Several modifications (e.g. methylations) have been identified for different RNA types. Current evidence shows that chemical RNA modifications can influence the whole molecule's secondary structure, translatability, functionality, stability, and degradation, and some are dynamically and reversibly modulated. miRNAs, in particular, are not only post-transcriptional modulators of gene expression but are themselves submitted to regulatory mechanisms. Understanding how these modifications are regulated and the resulting pathological consequences when dysregulation occurs is essential for the development of new therapeutic targets. In humans and other mammals, dietary components have been shown to affect miRNA expression and may also induce chemical modifications in miRNAs. The identification of chemical modifications in miRNAs (endogenous and exogenous) that can impact host gene expression opens up an alternative way to select new specific therapeutic targets. Hence, the aim of this review is to briefly address how RNA epitranscriptomic modifications can affect miRNA biogenesis and to summarize the existing evidence showing the connection between the (de)regulation of these processes and disease settings. In addition, we hypothesize on the potential effect certain chemical modifications could have on the potential cross-kingdom journey of dietary plant miRNAs.
dc.identifier.doi10.1080/15476286.2021.2002003
dc.identifier.essn1555-8584
dc.identifier.issn1547-6286
dc.identifier.pmid34843412
dc.identifier.unpaywallURLhttps://www.tandfonline.com/doi/pdf/10.1080/15476286.2021.2002003?needAccess=true&role=button
dc.identifier.urihttps://hdl.handle.net/10668/26955
dc.identifier.wosID723460100001
dc.issue.number2
dc.journal.titleRna biology
dc.journal.titleabbreviationRna biol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.number586-599
dc.publisherTaylor & francis inc
dc.rights.accessRightsopen access
dc.subjectEpitranscriptomics
dc.subjectmiRNA modifications
dc.subjectmethylation
dc.subjectm(6)A
dc.subjectcross-kingdom
dc.subjectM(6)a rna methylation
dc.subjectLet-7 microrna expression
dc.subjectMessenger-rna
dc.subjectPlant micrornas
dc.subjectGene-expression
dc.subjectYth domain
dc.subjectN-6-methyladenosine rna
dc.subjectStructural basis
dc.subjectBreast-cancer
dc.subjectPromotes
dc.titleUp-to-date on the evidence linking miRNA-related epitranscriptomic modifications and disease settings. Can these modifications affect cross-kingdom regulation?
dc.typereview
dc.type.hasVersionVoR
dc.volume.number18
dc.wostypeReview

Files